The potential to use CAR-T therapy in mesothelioma has been explored fairly extensively, and pre-clinical models using various targets including mesothelin (MSLN) [120, 121], Fibroblast activation protein (FAP) [122], Met Proto-oncogene (cMET) [123], pan-ErbB [124] and others have been extensively tested [125, 126]. The gene discussed is MSLN; the disease is mesothelioma.